Cargando…
An Adaptive Physiologically Based Pharmacokinetic–Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers
Molibresib (GSK525762), an orally bioavailable small molecule with 2 major equipotent active metabolites, is being developed for the treatment of cancers. Molibresib is a substrate of cytochrome P450 (CYP) 3A4 and P‐glycoprotein (P‐gp). To enable administering safe doses of molibresib to healthy vol...
Autores principales: | Riddell, Kylie, Patel, Aarti, Collins, Gary, Zhou, Yanyan, Schramek, Dan, Kremer, Brandon E., Ferron‐Brady, Geraldine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754455/ https://www.ncbi.nlm.nih.gov/pubmed/32820548 http://dx.doi.org/10.1002/jcph.1711 |
Ejemplares similares
-
Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors
por: Piha-Paul, Sarina A, et al.
Publicado: (2019) -
Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: A semimechanistic autoinduction model
por: Krishnatry, Anu Shilpa, et al.
Publicado: (2021) -
Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole
por: Martin, Paul, et al.
Publicado: (2012) -
Exposure–response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors
por: Krishnatry, Anu Shilpa, et al.
Publicado: (2021) -
Effect of Rifampicin on the Pharmacokinetics of Evogliptin in Healthy Volunteers
por: Shin, Yesong, et al.
Publicado: (2022)